Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20110420 | 0.90 | TP53 (0.60) | TP53 | |
| SCHEMBL6032487 | 0.82 | MAPT (0.61) | LMNAALDH1A1MAPTUSP2POLB | |
| SCHEMBL3679894 | 0.81 | ALDH1A1 (0.78) | LMNAALDH1A1MAPTTP53KDM4E | |
| SCHEMBL19771115 | 0.79 | ALDH1A1 (0.74) | LMNAALDH1A1MAPTGAAHPGD | |
| SCHEMBL2740205 | 0.78 | TP53 (0.47) | LMNAALDH1A1MAPTUSP2POLB | |
| SCHEMBL25916475 | 0.76 | MAPT (0.70) | LMNAALDH1A1MAPTUSP2POLB | |
| SCHEMBL21989742 | 0.75 | KDM4E (0.59) | LMNAALDH1A1MAPTUSP2POLB | |
| SCHEMBL7107990 | 0.74 | LMNA (0.60) | LMNAALDH1A1MAPTUSP2POLB | |
| SCHEMBL10291165 | 0.74 | MAPT (0.63) | ALDH1A1MAPTUSP2POLBL3MBTL1 | |
| SCHEMBL9902123 | 0.74 | LMNA (0.91) | LMNAALDH1A1MAPTUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| US-7144893-B2 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-11-04 | — | — | US | disclosed |
| EP-1404659-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | TXNRD3, TXNRD1, TXN | LMNA 3156/4885ALDH1A1 245/4885MAPT 4098/4885 |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | LMNA 3622/4885ALDH1A1 556/4885MAPT 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.